Becker's Healthcare October 23, 2024
Alexandra Murphy

The FDA approved Pfizer’s Abrysvo, the first and only RSV vaccine for adults aged 18 to 59 who are at increased risk of severe respiratory illness caused by RSV.

The approval is based on data from Pfizer’s Phase 3 MONeT trial, which evaluated the vaccine’s safety and efficacy in high-risk adults, according to an Oct. 22 news release from...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, FDA, Govt Agencies, Healthcare System, Patient / Consumer, Pharma / Biotech, Provider, Public Health / COVID
Crackdown on Homeless Encampments Raises Public Health Questions
Beyond Floppy Disks And Fax Machines: Modernizing Immunization Information Systems
XEC poised to become dominant COVID variant: Preprint study
PCPs Can Help Ease This ‘Public Health Catastrophe’
Cancer detection recovered following pandemic disruptions

Share This Article